Death receptor 4 (DR4; also called TRAIL-R1), a member of the tumor necrosis factor receptor superfamily, is a cell surface receptor that triggers the apoptotic machinery upon binding to its ligand tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Although several chemotherapeutic agents were reported to induce DR4 expression, the mechanism of this eect remains largely unknown. To begin to understand its regulation, we cloned a 1.8 Kb 5'-flanking region of the human DR4 gene and identi®ed several putative binding sites for transcription factors including activator protein 1 (AP-1). Among the three putative AP-1 binding sites, the site located at 7350/7344 is functionally active as evidenced by a combination of electrophoretic mobility shift and luciferase reporter assays. The AP-1 activator phorbol 12 ± myristate 13-acetate (TPA) enhanced the binding of this DR4 AP-1 binding site to protein(s) in a nuclear extract from TPAtreated cells, increased luciferase activity of a reporter construct containing this site and induced DR4 expression at the transcription level. These results indicate that AP-1 regulates DR4 expression via the AP-1 binding site located at 7350/7344. AP-1 has been implicated in many critical cellular processes including apoptosis, and is a major target of the c-Jun NH 3 -terminal kinase signaling pathway that is activated by many anticancer drugs. Therefore, our ®ndings may increase the understanding of the mechanisms underlying AP-1-mediated apoptosis as well as drug-induced apoptosis.
Introduction
Tumor necrosis factor (TNF)-related apoptosis-inducing agent (TRAIL; also called APO-2L), a newly identi®ed member of the TNF family, has attracted much attention recently because it induces apoptosis in a wide variety of transformed cells but does not seem to be cytotoxic to normal cells in vitro (Wiley et al., 1995; Pitti et al., 1996; Ashkenazi and Dixit, 1999) . Histological analysis of TRAIL-treated tumors revealed an increase in apoptotic cells and con®rmed TRAIL's ability to induce apoptosis in vivo in an animal model without toxicity toward normal tissue Walczak et al., 1999) . Thus, TRAIL diers from its related death ligands TNF and Fas ligand (FasL), which, in addition to inducing apoptosis in cancer cells, cause an in¯ammatory response and liver damage, respectively, when administered systemically (Ashkenazi and Dixit, 1998) . Therefore, TRAIL is considered to be a tumor-selective apoptosis-inducing cytokine and a promising new candidate for cancer treatment (Ashkenazi and Dixit, 1998; French and Tschopp, 1999; Fricker, 1999; Nagane et al., 2001) . It was recently reported that recombinant human TRAIL induced apoptosis in vitro in isolated human but not non-human hepatocytes, raising the concern that TRAIL therapy might cause hepatotoxicity (Jo et al., 2000) . However, the latest study has demonstrated that the cytotoxicity of TRAIL to human hepatocytes or to normal human keratinocytes is largely due to inappropriate preparation of recombinant human TRAIL (Lawrence et al., 2001; Qin et al., 2000) .
TRAIL induces apoptosis by interacting with two death domain-containing receptors: DR4 (also known as TRAIL-R1) and DR5 (also called TRAIL-R2, TRICK2 and KILLER/DR5) Dixit, 1998, 1999) . In addition, TRAIL can bind to three decoy receptors DcR1 (TRAIL-R3 or TRID), DcR2 (TRAIL-R4 or TRUNDD) and osteoprotegerin (OPG). These receptors that contain either no cytoplasmic death domain or a truncated death domain can compete with DR4 and DR5 for TRAIL binding and thereby act as negative regulators of TRAIL's eect Dixit, 1998, 1999) .
DR4 is the ®rst death receptor for TRAIL to be identi®ed (Pan et al., 1997) . Overexpression of DR4 leads to either ligand-dependent (Pan et al., 1997) or -independent apoptosis. Like DR5, the DR4 apoptotic signaling pathway involves activation of multiple caspases including caspase-10, -8, -7, -6 and -3 and subsequent cleavages of poly(ADPribose)polymerase (PARP) and DNA fragmentation factor 45 (DFF45) . A recent study demonstrated that it is the expression level of DR4 rather than the expression level of DR5, DcR1 and DcR2 that correlates with TRAIL sensitivity . Another study showed that homozygous deletion of the DR4 gene in a nasopharyngeal cancer cell line is associated with TRAIL resistance (Ozoren et al., 2000) . Therefore, these studies suggest that DR4 may be one of the most important molecular determinants of response to TRAIL in the killing of normal and tumor cells. In addition, it was reported recently that two alterations in the ectodomain of DR4 occur in increased frequency in lung cancer, head and neck squamous cells carcinoma and gastric adenocarcinoma, suggesting that mutation of the DR4 gene may contribute to tumorigenesis or be a marker for predisposition to malignancy (Fisher et al., 2001) . Another report showed that the increased rate of mutations in DR4 death domain was detected in metastatic lesions of breast cancer, suggesting that mutation of the DR4 gene may also be related to cancer metastasis (Shin et al., 2001) .
It was reported that some DNA-damaging agents are able to induce DR4 expression (Gibson et al., 2000; Nagane et al., 2000; Ravi et al., 2001; Guan et al., 2001) . Except for the recent reports by others (Ravi et al., 2001 ) and ourselves (Guan et al., 2001 ) that DR4 expression is regulated by p53 and NF-kB, respectively, little is known about the regulation of DR4 gene expression, especially at the transcriptional level. In an eort to gain insight into the mechanism underlying regulation of DR4 expression, we cloned the 5'-flanking region of the human DR4 gene and found multiple potentially important putative consensus sequences for binding of transcription factors including AP-1. Therefore, in this study we focused on testing AP-1 regulation of DR4 expression and identi®ed a functional AP-1 binding site that is responsible for regulation of DR4 expression.
Results

Cloning of the 5'-flanking region of the human DR4 gene
Three overlapping 5'-flanking regions of the human DR4 ranging in size from 0.7 to 5.8 Kb were ampli®ed by nested PCR from two of the ®ve restriction-digested adaptor-ligated genomic libraries using two DR4 speci®c primers (GSP-1 and GSP-2) and two adaptor primers (AP1 and AP2). The EcoR V library yielded 1.8 Kb product whereas SspI library generated 0.7 and 5.8 Kb products, which were cloned and sequenced. All three fragments share overlapping or identical sequences, indicating that they represent dierent lengths of 5'-flanking region of the DR4 gene. We, therefore, focused our studies on analysing the 1.8 Kb 5'-flanking region (Figure 1) .
The transcription start site was determined by primer extension analysis using a primer antisense to the known 5' flanking region and ATG of DR4 gene. Two elongation products were identi®ed from the total RNA of H1792 cells (Figure 2 , lane 2), but they were not produced when the primer extension reaction was carried in the absence of total RNA (lane 1). We refer to the most proximal transcription start site as + 1 (Figure 2) .
The nucleotide sequence of the 1.8 Kb 5'-flanking region of the DR4 gene and computer sequence Figure 1 Nucleotide sequence of 5'-flanking region of human DR4 gene. The transcription start site is indicated by a bent arrow and designated at + 1. Three putative AP-1 binding sites were underlined and indicated as boldface, which were designated as AP-1/I, AP-1/II and AP-1/III, respectively. The core sequences of other important transcription factors such as Sp1, MyoD and NFAT were also underlined and indicated Figure 2 Determination of the human DR4 mRNA transcription start site by primer extension analysis. Fifty mg of total RNA from the human lung carcinoma cells H1792 (lane 2) was annealed to the antisense oligonucleotide described in Materials and methods. The extension was also performed without RNA, as a negative control (lane 1). The arrows indicate anticipated transcription start sites, and + 1 corresponds to the most proximal site. The four lanes to the left contain pGL3-Basic sequence product used as a size marker analysis using TRASFAC 4.0 software through the internet service revealed the presence of several putative binding sites for transcription factors including activator protein 1 (AP-1), Sp1, NFAT and MyoD (Figure 1 ). There are three putative AP-1 binding sites, which were designated as Ap-1/I, AP-1/II and AP-1/ III, respectively (Figure 1) . The core sequence of AP-1/ I (TGAATCA) is more identical than AP-1/II (TTACTCA) and AP-1/III (TCAATCA) to the consensus sequence of standard AP-1 site [TGAG(/ C)TCA] (Wisdom, 1999) . The proximal 5'-flanking region of DR4 lacks a typical TATA box but contains a perfect Sp1 consensus sequence (729/720) and a MyoD consensus sequence (745/740). Serial 5'-deletions of the 5'-flanking region of the DR4 gene and analysis of their promoter activities suggested that the 1.8 Kb DR4 5'-flanking region had strong promoter activity and that the necessary regulatory elements for basic DR4 promoter activity were located in sequences between 7117 and 719 (data not shown). Furthermore, we were able to detect intense bands corresponding to complexes bound to Sp1 and MyoD binding sites within this region by an electrophoretic mobility shift assay (EMSA) (data not shown), suggesting that they may contribute to the basic promoter activity of the DR4 gene.
TPA induces the expression of the DR4 gene
The identi®cation of three putative AP-1 binding sites in the DR4 promoter region was intriguing and has led to the hypothesis that AP-1 may regulate DR4 expression if any of the three putative AP-1 binding sites is functionally active. To test this, we ®rst examined the eect of phorbol 12-myristate 13-acetate (TPA), a well-known and potent AP-1 activator, on DR4 expression in human cancer cells. As we expected, TPA exhibited a time-dependent induction of DR4 expression at the mRNA level in both H1792 and PC-3 cells ( Figure 3a ). The induction of DR4 expression rapidly reached a peak at 3 h after the cells were exposed to TPA (Figure 3a ). In fact, we were able to detect induction of DR4 expression by TPA as early as at 1 h (data not shown). Interestingly, we did not ®nd a clear dose-dependent induction of DR4 expression by TPA at concentrations ranging from 5 nM to 100 nM ( Figure 3b ). However, we did ®nd a dose dependent induction of DR4 expression when cells were treated with TPA at concentrations ranging from 0.5 nM to 5 nM (data not shown). By Western blot analysis, we also detected an increase of DR4 protein level after treatment with TPA in both cell lines (Figure 3c ). Furthermore, we found that TPA-induced DR4 mRNA expression was completely inhibited by the transcription inhibitor actinomycin D (Act D) ( Figure  3d ), indicating that TPA induces DR4 expression at the transcriptional level. Cycloheximide (CHX) alone induced the expression of DR4 mRNA (Figure 3d ). At the present time, we do not know the mechanism by which CHX induces DR4 expression. It is possible that CHX may inhibit the synthesis of certain proteins that negatively regulate DR4 expression or induces DR4 expression independent of its inhibitory eect on protein synthesis. Nonetheless, CHX partially suppressed DR4 induction by TPA (Figure 3d ).
Identification of putative AP-1 binding sites responsible for AP-1 regulation of DR4 expression
To determine whether TPA activates AP-1 and identify the putative AP-1 binding sites that are responsible for TPA-induced AP-1 transcription and DR4 expression, we performed EMSA analysis. This analysis has enabled us to examine whether nuclear extracts from TPA-treated cells have more binding capacity to putative AP-1 binding sites in DR4 promoter and whether AP-1 binding is speci®c. As shown in Figure 4a Furthermore, we con®rmed and located the putative AP-1 binding sites that are functionally active by analysing the luciferase reporter constructs carrying dierent deletions or mutations of the putative AP-1 binding sites in DR4 promoter. As shown in Figure 5a , the constructs containing 71773/+63 and 71121/+63 fragments that maintain three putative AP-1 binding sites, and the construct containing 7586/+63 fragment in which the AP-1/III site was deleted had comparable (Figure 5b ). In agreement with the demonstration generated from the EMSA, it appears that the AP-1/I located at 7350/7344 in the DR4 promoter region has functional AP-1 binding activity, which may be responsible for AP-1 regulation of DR4 expression.
Lastly, we further examined the eects of TPA treatment on luciferase activity of constructs with and without AP-1/I site. We found that TPA was able to increase transcription activity of pGL3(71733/+63) and pGL3(7586/+63), which contain AP-1/I site, but not that of pGL3(7208/+63), which does not have AP-1/I site (Figure 5c ). This result indicates that TPA can indeed increase DR4 transcription through the AP-1 binding site (i.e. AP-1/I) in the DR4 promoter. 
Discussion
In this study, we cloned and analysed a 1.8 Kb 5'-flanking region of the human DR4 gene, which exhibited strong promoter activity. Database analysis of this sequence revealed several putative binding sites for transcription factors including AP-1. AP-1 transcription factor has been implicated in regulation of apoptosis (Shaulian and Harin, 2001), whereas DR4 is a death receptor that can directly trigger apoptotic machinery upon binding to its ligand (Ashkenazi and Dixit, 1998) . Therefore, the identi®-cation of three putative binding sites for AP-1 (i.e. TRE, TPA response element) in the DR4 promoter region attracted our attention. Our initial study showed that TPA, a well-known strong AP-1 activator, induced rapid DR4 expression at both mRNA and protein levels in both tested cancer cell By combination of the EMSA and the luciferase reporter assay for analysis of the importance of each AP-1 binding site, we demonstrated that the putative AP-1 binding site located at 7350/7344 was functionally active. TPA strongly increased the binding of this AP-1 binding site to nuclear extracts from TPA-treated cells and luciferase activity of the reporter construct containing this site. Therefore, we conclude that AP-1 is involved in regulation of DR4 expression via the AP-1 binding site located at 7350/7344. To the best of our knowledge, this is the ®rst report on the cloning of DR4 promoter and on AP-1 regulation of DR4 expression. AP-1 is a homodimer (e.g. Jun : Jun) or heterodimer (e.g. Jun : Fos) composed mainly of basic region-leucine zipper proteins that belong to the Jun (c-Jun, JunB and JunD) and Fos (c-Fos, Fos B, Fra-1 and Fra-2) families (Wisdom, 1999; Shaulian and Harin, 2001) . By performing gel supershift assays, we found that AP-1 (7350/7344) complex induced by TPA treatment could be supershifted by additions of antibodies speci®c to c-Jun, Jun B, Jun D, Fos B and Fra-1, respectively. This suggests that the AP-1 complex bound to the AP-1 binding site in DR4 promoter region is a heterodimer composed of c-Jun, JunB or JunD dimerized with Fos B or Fra-1.
AP-1 has long been identi®ed as an immediateearly activator of transcription that is important in proliferation and cellular transformation. Recently, this transcription factor has also been implicated in the process of apoptosis under certain circumstances such as in response to stress or growth factor withdrawal (Wisdom, 1999; Shaulian and Harin, 2001 ). However, it remains unclear how it induces or mediates this process. One possibility is that AP-1 ) and pGL3-basic] were transiently transfected into H1792 cells using FuGene 6. Six hours later, cells were treated with 50 ng/ ml TPA for 24 h before they were harvested for luciferase assay. Column, means of triplicate determinations; bars, s.d. Dixit, 1998; Green, 2000) . Indeed several recent reports suggest that AP-1 induces FasL expression via the AP-1 binding sites in FasL promoter, which contributes to apoptosis induced by certain types of anticancer drug (Kasibhatla et al., 1998; Le-Niculescu et al., 1999; Kolbus et al., 2000; Eichhorst et al., 2000) . Our ®ndings in the present study indicate that AP-1 may mediate apoptosis via not only regulation of death ligands (e.g. FasL) but also regulation of death receptors (e.g. DR4), which extends our current understanding of the mechanism underlying AP-1 mediated apoptosis. We (Guan et al., 2001 ) and others (Gibson et al., 2000; Nagane et al., 2000) previously showed that some DNA-damaging agents induce DR4 expression. We found that induction of DR4 expression by DNA damaging agents such as etoposide (VP16) and doxorubicin (DOX) could be either p53-dependent in some types of cancer cell such as lung cancer cells, or p53-independent in other types of cancer cell such as prostate and breast cancer cells (Guan et al., 2001) . There are few reports dealing with the issue of p53-independent regulation of DR4 expression and its role in drug-induced apoptosis. NF-kB was recently reported to upregulate DR4 expression, but there is no evidence for direct regulation of DR4 by NF-kB at the transcriptional level (Ravi et al., 2001) . Our study is the ®rst one to show that the transcription factor AP-1 directly upregulates DR4 expression at the transcriptional level via binding to an AP-1 binding site in the DR4 promoter. Because our studies were performed in cell lines such as H1792 or PC-3 that have either mutant p53 or p53-null, our ®nding that AP-1 regulates DR4 expression is particularly important for understanding p53-independent regulation of death receptor genes. AP-1 is a major target of the c-Jun NH 3 -terminal kinase (JNK) signaling pathway (Karin, 1995) by phosphorylating the transactivation domain of c-Jun leading to an increase in its transactivation potential, whereas JNK is often activated by many anticancer drugs including DNA damaging agents (Osborn and Chambers, 1996; Kasibhatla et al., 1998; Wang et al., 1998; Watabe et al., 1998; Kolbus et al., 2000; Eichhorst et al., 2000; Fan et al., 2001) . Our preliminary results showed that some anticancer drugs such as the DNA damaging agents DOX and VP16 and the retinoid CD437 can indeed increase AP-1 transcriptional activity of the DR4 promoter (Guan and Sun, unpublished data) . Therefore, our current ®nding that AP-1 regulation of DR4 expression will be also helpful for elucidating the mechanism(s) by which anticancer drugs induce apoptosis.
Materials and methods
Cell lines
H1792 human lung adenocarcinoma cells and PC-3 human prostate cancer cells were purchased from the American Type Cell Culture (ATCC; Rockville, MD, USA). These cells were grown in monolayer culture in a 1 : 1 (v/v) mixture of Dulbecco's modi®ed Eagle's medium and Ham's F12 medium supplemented with 5% FBS and antibiotics (penicillinstreptomycin) at 378C in a humidi®ed atmosphere consisting of 5% CO 2 and 95% air.
Cloning and sequencing of the 5'-flanking region of the human DR4 gene
The 5'-flanking region (&1.8 Kb) of the human DR4 gene was isolated using the Human Genome Walker Kit (Clontech, Palo Alto, CA, USA) according to the manufacturer's instructions. A primer GSP-1: 5'-TGCGCTCCCGGGATTCGGAGTCACTG-3', which is complementary to the 5' end sequence 44 ± 69 of DR4 cDNA (Accession No. U90875) was used with an outer adaptor primer AP1 for primary PCRs using ®ve adaptorligated restriction digested human genomic libraries as templates. The primary PCR products were then reampli®ed with a nested DR4 gene speci®c primer GSP-2: 5'-AACGCACCTAGATGTACTCTAGCTGGTG-3', which is complementary to the 5' end sequence 11 ± 38 of DR4 cDNA, and a nested adaptor primer AP2. A &1.8 Kb secondary PCR product from the EcoRV library was cloned into a pCR2.1-TOPO vector (Invitrogen, San Diego, CA, USA) and sequenced at the Institutional DNA Sequencing Core Facility (MD Anderson Cancer Center, Houston) using the¯uorescence-labeled automatic sequencing approach. The sequence of the DR4 5'-flanking region was deposited in Genebank under accession No. AY033911.
Construction of luciferase reporter plasmids carrying different deletion or point mutation of the DR4 5'-flanking region
To construct luciferase reporter plasmids with serial deletions of 5'-flanking region of the DR4 gene, fragments generated with either PCR ampli®cation or restriction digestion were subcloned into the promoterless pGL3-basic luciferase reporter vector (Promega, Madison, WI, USA). To make pGL3(71733/+63) and pGL3(7208/+63) constructs, the following synthetic oligonucleotides were used for PCR ampli®cation using 1.8 Kb DR4 5'-flanking region in pCR2.1-TOPO as a template: sense strand 5'-ACTA-TAGGGCACGCGTGGTCGACGG-3' for 71733/+63 fragment and 5'-CGACGCGTGCTGAGGTCAACTCCC-GACC-3' for 7208/+63 fragment and antisense strand 5'-GGCGCTAGCTCATCCTGCCAGGTCAATCCAAGAAG-CAG-3' for both. The PCR products were then digested with MluI/NheI and subcloned into pGL3-basic luciferase vector. The other deletion constructs were generated from pGL3(71733/+63) using various restriction enzymes as follows: Acc 65I for pGL3(71061/+63) and SacI for pGL3(7586/+63). The composition of the constructs was con®rmed by restriction enzyme digestion and by DNA sequencing.
Point mutations of putative AP-1 binding sites were made via site-directed mutagenesis using the QuikChange Sitedirected Mutagenesis Kit (Stratagene, La Jolla, CA, USA) following the manufacturer's instructions. The primers used for mutations of AP-1/I (7350/7344) and AP-1/II (7487/ 7481) were 5'-GGCAGGCTGAATTGCTCGCCCGGTAG-3' and 5'-CCCAGTTACTTGGGAGGCTGAGGCAG-3', respectively. Putative binding sites were underlined and point mutations were indicated as boldface. Mutations were con®rmed by DNA sequencing.
Primer extension analysis
Primer extension was carried out as described previously (Sambrook et al., 1989) . The antisense oligonucleotide 5'-CATCCTGCCAGGTCAATCCAAGAAGCAGCGTGC-3' was hybridized with 50 mg of total RNA isolated from human DR4 expressing H1792 cells. The ®rst strand cDNA was synthesized with Primer Extension System-AMV Reverse Transcriptase (Promega) at 428C for 30 min in the presence of 32 P-labeled oligonucleotide and the fragments produced were analysed by 6% denaturing long ranger sequencing gel (FMC BioProducts, Rockland, ME, USA) electrophoresis.
EMSA
Nuclear extract from H1792 or PC-3 cells was prepared as previously described (Pollock and Treisman, 1990) . EMSA was carried out using the Gel-shift Assay Kit (Promega) following the manufacturer's manual. The synthetic double stranded oligonucleotides containing each potential AP-1 binding site as indicated below were labeled with [g-32 P] ATP (4000 Ci/mol; ICN Radiochemicals, Irvine, CA, USA) using T4 polynucleotide kinase: AP-1/I (7350/7344) (5'-GGCAGGCTGAATCACTCGCCCGG-3'), AP-1/II (7487/ 7481) (5'-TCCCAGTTACTCAGGAGGCTG-3') and AP-1/ III (71022/71016) (5'-TGAACATCAATCAGCGCCC-3').
The unlabeled synthetic double-stranded oligonucleotides containing either canonical (as presented above) or mutated (as follows) consensus sequences were used for competition assays: mutated AP-1/I (7350/7344) (5'-GGCAGGCT-GAATTGCTCGCCCGG-3'), mutated AP-1/II (7487/ 7481) (5'-TCCCAGTTACTTGGGAGGCTG-3'), and mutated AP-1/III (71022/71016) (5'-TGAACAT-CAATTGGCGCCC-3'), where the mutations were shown as boldface. The synthetic oligonucleotides containing standard AP-1 and Sp-1 consensus sequences were purchased from Promega. For each competition assay, an approximately 100-fold molar excess of unlabeled competitor oligonucleotide was preincubated with the given nuclear extract for 10 min at room temperature before the labeled probe was added.
For the gel supershift assay, each antibody (0.5 mg) was preincubated with the given nuclear extract for 30 min at room temperature before addition of the labeled probe. Speci®c antibodies for c-Jun, Jun B, Jun D, c-Fos, Fos B, Fra-1 and Fra-2 were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Transient transfection and luciferase activity assay pAP1-Luc reporter plasmid, which contains the luciferase reporter gene driven by a basic promoter element (TATA box) joined to seven repeats of AP-1 binding sites, was purchased from Stratagene (La Jolla, CA, USA) and used as a positive control for AP-1 activity. pCH110 plasmid encoding bgalactosidase (b-gal) was purchased from Pharmacia Biotech (Piscataway, NJ, USA). All plasmids used for luciferase assay were puri®ed with QIAGENE/Filter Plasmid Maxi Kit (QIAGEN, Chatsworth, CA, USA). For transient transfection, cells were seeded in 24-well plates and co-transfected with the given reporter plasmid and pCH110 plasmid using FuGene 6 transfection reagent (Roche Molecular Biochemicals, Indianapolis, IN, USA) following the manufacturer's protocol. After 24 h, luciferase activity was measured using luciferase assay system (Promega) using a luminometer. Relative luciferase activity was normalized to b-gal activity, which was measured as described previously (Pfahl et al., 1990) .
Northern blot analysis
Preparation of total cellular RNA and the Northern blot analysis were performed as described previously (Sun et al., 1997) . Twenty mg of total RNA were loaded in each lane. Human DR4 and GAPDH cDNAs were purchased from Alexis Biochemicals (San Diego, CA, USA) and Ambion, Inc. (Austin, TX, USA), respectively.
Western blot analysis
Whole cell lysates were prepared as described previously (Sun et al., 1999) and the protein concentration was determined using the Protein Assay Kit (Bio-Rad, Hercules, CA, USA). Protein (50 mg) was electrophoresed through a 10% denaturing polyacrylamide slab gel and transferred to a Hybond ECL membrane (Amersham, Arlington Heights, IL, USA) by electroblotting. The blot was probed with the mouse monoclonal anti-DR4 antibody (clone 32A1280; Imgenex, San Diego, CA, USA), stripped and reprobed with rabbit polyclonal anti-b-actin antibody (Sigma Chemical Co., St. Louis, MO, USA). Antibody binding was detected using the ECL system (Amersham).
